Synarc Research Laboratory (beijing) Ltd.

Hebei Yanda Ludaopei Hospital

Xueying Wu

Hui Wang

Aixian Wang

Man Chen

Qing Du

Ya Guo

Junyi Zhen

Meiwei Gong

Disclosed are an antibody combination for one-step screening and/or diagnosis of clonal diseases and application thereof. The antibody combination includes eight groups of antibodies, and is a set of flow cytometry detection panels for one-step screening and/or diagnosis of clonal diseases, and 5-tube parallel is used for one sample, the first group of antibodies and the second group of antibodies are used for samples in different flow cytometry tubes, the third group of antibodies and the sixth group of antibodies are used for samples in the same flow cytometry tube, the fourth group of antibodies and the seventh group of antibodies are used for samples in the same flow cytometry tube, and the fifth group of antibodies and the eighth group of antibodies are used for samples in the same flow cytometry tube.

Antibody combination for one-step screening and/or diagnosis of clonal diseases and related application

The present invention provides a reagent composition for detection of a non-hematopoietic tumor and use thereof. Said reagent composition includes three sets of antibodies, with the first set of antibodies including an anti-CD9 antibody, an anti-GD2 antibody, an anti-CD3 antibody, an anti-CD4 antibody, an anti-CD56 antibody, an anti-CD36 antibody, an anti-CD81, and an anti-CD45 antibody; the second set of antibodies including an anti-HLA-ABC antibody, an anti-CD38 antibody, an anti-CD19 antibody, an anti-CD56 antibody, an anti-CD36 antibody, an anti-CD7 antibody, and an anti-CD45 antibody; the third set of antibodies including anti-cytoplasmic cytokeratin antibodies; wherein the first set of antibodies and the second set of antibodies are respectively used for samples in separate tubes, and the third set of antibodies is used for the sample in the same tube as the second set of antibodies. The reagent composition of the present invention can be applied for flow cytometry screening, diagnosis and/or follow-up detection of a non-hematopoietic tumor.

Reagent composition for detection of non-hematopoietic tumor and use thereof

The present invention provides a detection reagent and therapeutic target for B cell tumor after targeted therapy and related applications. The reagent composition comprises 3 groups of antibodies, with the first group of antibodies including an anti-CD38 antibody, an anti-CD10 antibody, an anti-CD34 antibody, an anti-CD19 antibody, an anti-CD24 an antibody, an anti-CD20 antibody, an anti-CD81 antibody, an anti-CD45 antibody; the second group of antibodies including an anti-CD38 antibody, an anti-CD10 antibody, an anti-CD34 antibody, an anti-CD19 antibody, an anti-CD20 antibody, an anti-CD72 antibody, an anti-CD45 antibody; and the third group of antibodies including an anti-cytoplasmic CD79a antibody. The reagent composition of the present invention can be applied for the detection of B-lymphocyte tumors after targeted therapy by flow cytometry.

Detection reagent and therapeutic target for B cell tumor after targeted therapy and related application

Growing community of inventors

Beijing, China

Xueying Wu